This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The end-use segments analyzed are Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the USA, Japan, Europe, and Rest of World. Annual forecasts are provided for each region and product segment for the period of 2000 through 2010. The report profiles 15 companies including many key and niche players worldwide such as Allergan, Inc., Ipsen Group, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 3 $100     Study Reliability and Reporting Limitations.....I-1         Disclaimers.....I-2 Data Interpretation & Reporting Level.....I-2         Product Definitions and Scope of Study.....I-3 Cosmetic Applications.....I-3 Therapeutic Applications.....I-3     II. EXECUTIVE SUMMARY 43 $2250   1. Industry Overview.....II-1 4  $400       ‘Bright’ Outlook Forecast for Botulinum Toxin.....II-1 Fastest Growth Forecast for Cosmetic Applications.....II-1 Upbeat Projections for Therapeutic Applications.....II-1 US Corners a Lion’s Share.....II-1 Growth Drivers for Botulinum Toxin.....II-1 1 $100     Market Dynamics.....II-2 Combination Therapy Supports Market Growth.....II-2 Botulinum Toxin and Soft Tissue Filling Agents.....II-2 Botulinum Toxin Injections and Laser Resurfacing.....II-2 Botulinum Toxin and Phenol.....II-2 1 $100     Technological Innovations Drive Botulinum Market.....II-3 Changing Consumer Belief.....II-3 Under-Treated Diseases Boost Demand for Off- Label Products.....II-3 Burgeoning Consumer Awareness.....II-3 ‘Feeling’ to Look Good - Driving Aesthetic Market.....II-3 1 $100     Expansion of Financing Services to Propel Growth.....II-4 Adverse Effects Impedes Market Growth.....II-4 High Cost – A Major Market Restraint.....II-4 Concern over Long-Term Side Effects.....II-4 1 $100   2. Competitive Landscape.....II-5 5  $500       Allergan Dominates Global Botulinum Toxin Market.....II-5 Table 1: Revenues of Allergan, Inc (2001-2005): Net Sales of Botox®/Neuromodulator (In US$ Million) (includes corresponding Graph/Chart).....II-5 1 $100     Botox Dominance Remains Stable in the Global Market.....II-6 Clinical Trails in Progress for Botox.....II-6 Ipsen – Major Player in Botulinum Toxin Market.....II-6 Table 2: Revenues of Ipsen Group (2004 & 2005): Net Sales of Dysport® (In € Million).....II-6 1 $100     Clinical Trails in Progress for Dysport.....II-7 Solstice - Only Global Manufacturer of Type B Botulinum Toxin.....II-7 Table 3: Leading Players in Global Botulinum Toxin (Therapeutic) Market (2005): Percentage Breakdown by Revenues for Allergan (Botox®), Solstice (Myobloc®), Ipsen and (Dysport®) (includes corresponding Graph/Chart).....II-7 Table 4: Leading Players in Global Botulinum Toxin (Cosmetic) Market (2005): Percentage Breakdown by Revenues for Allergan (Botox®), Ipsen (Dysport®/ Reloxin®), and Others (includes corresponding Graph/Chart).....II-7 1 $100     Worldwide Botulinum Toxin Market (2005): Competitors Profile of the Top 2   Companies.....II-8 Comparison of Allergan’s Botox® and Ipsen’s Reloxin®.....II-8 1 $100     Table 5: Worldwide Botulinum Toxin Market (2005 & 2006): Percentage Breakup by Key Products – Botox®, Dysport®, Myobloc®, and Others® (includes corresponding Graph/Chart).....II-9 1 $100   3. Product Overview.....II-10 25  $2500       Botulinum Toxin – An Introduction.....II-10 1 $100     Chemical Overview.....II-11 Mechanism of Botulinum Toxin.....II-11 Side Effects.....II-11 1 $100     Immunogenicity Effects Response to Botulinum Therapy.....II-12 A Peek into the History and Development.....II-12 1 $100     Botulinum Toxin – A Classification.....II-13 Botulinum Toxin Type A.....II-13 Botox®.....II-13 1 $100     Historical Timeline of Botox: 1885-2002.....II-14 1 $100     Botox Approvals and Indications in Select Global Regions.....II-15 Dysport®.....II-15 Xeomin®.....II-15 Botulinum Toxin Type B.....II-15 1 $100     Myobloc®.....II-16 Key Products in Botulinum Toxin Type A, Type B.....II-16 1 $100     Competitive Overview of Botox® - Cosmetic Purpose (Smoothing of Facial   Wrinkles).....II-17 Other Types.....II-17 Applications of Botulinum Toxin.....II-17 Botulinum – Toxin or Treatment?.....II-17 1 $100     Therapeutic Applications of Botulinum Toxin.....II-18 Botulinum Toxin for Movement Disorders.....II-18 Botulinum Toxin Cures Dystonia.....II-18 1 $100     Botulinum is Beneficial for Cervical Dystonia.....II-19 Botulinum Toxin Cures Laryngeal Dystonia.....II-19 Ease from Writer’s Cramp.....II-19 1 $100     Botulinum – Useful To Treat Oromandibular Dystonia.....II-20 Tics.....II-20 Tremors.....II-20 Parkinson's Disease.....II-20 Botulinum Toxin Treats Hemifacial Spasm.....II-20 1 $100     Is Botulinum Toxin an Answer to Blepharospasm?.....II-21 Tantalizing Effect in Strabismus.....II-21 Childhood Strabismus.....II-21 1 $100     Botulinum Toxin Helps Spasticity Cure Better.....II-22 Stroke.....II-22 Traumatic Brain Injury.....II-22 Cerebral Palsy.....II-22 1 $100     Multiple Sclerosis.....II-23 Botulinum Toxin Soothes Pain.....II-23 Botulinum Heals Hypertonic Disorders.....II-23 1 $100     Cosmetic Applications of Botulinum Toxin.....II-24 Botulinum Toxin Irons Out Facial Wrinkles.....II-24 1 $100     Botulinum Lessens Facial Scarring.....II-25 Botulinum Toxin (Botox) Users Becoming Addictive.....II-25 Key Cosmetic Indications for Botulinum Toxin.....II-25 1 $100     Additional Applications.....II-26 Positive Response of Rigid Spine Syndrome to Botulinum Toxin.....II-26 Botulinum Toxin Effective in Bladder Dysfunctions.....II-26 1 $100     Botox Provides Respite from Tinnitus.....II-27 Botulinum Toxin for Anal Fissure.....II-27 Can Botox Prevent Baldness?.....II-27 Refractory Vaginismus and Botulinum.....II-27 1 $100     Botulinum Toxin Helps to Cure Dysphagia.....II-28 Encouraging Effects of Botox in Migraine.....II-28 Botulinum Eases Severe Facial Pain.....II-28 Botulinum Provides Relief from Pelvic Floor Pain.....II-28 1 $100     Botox Can Treat Children with Non-Neurogenic, Neurogenic Bladder.....II-29 Botulinum Toxin Finds Application in Cancer Treatment.....II-29 Botox Can Reduce Pain, Itching and Hand Eczema.....II-29 Botulinum Reduces Plantar Fasciitis Pain.....II-29 Botox Helps to Treat Carpal Tunnel Syndrome.....II-29 1 $100     Other Indications for Botulinum Toxin.....II-30 Terrorist and Military Exploitation of Botulinum Toxin.....II-30 Botulism – Infection from Botulinum.....II-30 1 $100     Types of Botulism.....II-31 Classical or Food Borne Botulism.....II-31 Home Canning – Culprit Behind Botulism.....II-31 1 $100     Wound Botulism.....II-32 Infant Botulism.....II-32 Botulism Outbreak in Animals.....II-32 1 $100     Safety Precautions.....II-33 Medicinal Investigations.....II-33 1 $100     Vaccine for Botulinum Toxin.....II-34 Technological Development.....II-34 US Inventor Develops New Fermentation Process.....II-34 1 $100   4. Recent Industry Activity.....II-35 4  $400       Allergan Rolls Out New Division with Acquisition of Inamed.....II-35 FTC Mandates Allergan Divest Rights to Reloxin.....II-35 Medicis Inks Agreement with Ipsen.....II-35 Solstice Neurosciences Inks Licensing Agreement with DreamPharma.....II-35 1 $100     Botox Enters India Market.....II-36 Mentor Begins Phase-I Clinical Trial on Botulinum Toxin .....II-36 Allergan Inks Agreement with GlaxoSmithKline.....II-36 DOR BioPharma Inks Agreement with Dowpharma.....II-36 Merz Pharma Receives Approval for Botulinum Toxin Type A.....II-36 1 $100     Mentor Initiates Phase-I Clinical Trial.....II-37 Mentor Establishes New Production Facility.....II-37 DOR BioPharma and Thomas Jefferson University Teams-Up with US Army.....II-37 Mentor Inks Licensing Agreement with WARF.....II-37 1 $100     Solstice Acquires World Rights for Myobloc.....II-38 Inamed Rolls Out Reloxin Brand.....II-38 1 $100   5. Focus on Select Ket Players.....II-39 2  $200       Allergan, Inc (USA).....II-39 Ipsen Group (France).....II-39 Metabiologics Inc, (USA).....II-39 Merz Pharmaceuticals GmbH (Germany).....II-39 1 $100     Mentor Corporation (USA).....II-40 Solstice Neurosciences, Inc. (USA).....II-40 1 $100   6. Global Market Perspective.....II-41 3  $300       Table 6: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region – US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-41 Table 7: World 10-Year Perspective for Botulinum Toxin by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2000, 2006 & 2010.....II-41 1 $100     Table 8: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region – US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II-42 Table 9: World 10-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2000, 2006 & 2010.....II-42 1 $100     Table 10: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region – US and Rest of World Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....II- 43 Table 11: World 10-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World for the Years 2000, 2006 & 2010.....II-43 1 $100 III. MARKET 21 $1950   1. The United States.....III-1 15  $1500       A. Market Analysis.....III-1 Botulinum Toxin Market to Grow at a Healthy Rate.....III-1 Botox Leads the US Botulinum Toxin Market.....III-1 Botox Growth - Largely Supported by FDA Approval for Cosmetic Use.....III-1 1 $100     Botox Approvals and Indications in the US.....III-2 Market Dynamics.....III-2 Booming Non-Surgical Treatments.....III-2 Aging Baby Boomers Drive Aesthetic Business.....III-2 Increasing Physician Base Impels Botulinum Market.....III-2 1 $100     Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin.....III-3 Increasing Off-label Use of Botulinum Toxin.....III-3 Medical Spas – Growing in Number.....III-3 Heightened Competition Limits Growth.....III-3 1 $100     Arduous Regulations Deter Product Progress.....III-4 Botulism Poisoning – A Major Concern.....III-4 Botox Injection – Popular Non-Invasive Cosmetic Procedure.....III-4 1 $100     Table 12: Number of Botox Injections (2000-2005) (includes corresponding Graph/Chart).....III-5 Table 13: Botox Injections by Gender (2004).....III-5 Table 14: Botox Injections by Age Group (2004) (includes corresponding Graph/Chart).....III-5 1 $100     Botox Attracts American Men.....III-6 Table 15: Non-Invasive Cosmetic Procedures in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices (includes corresponding Graph/Chart).....III-6 Table 16: Cosmetic Procedures (Surgical/Non-Surgical) in the US (2005): Percentage of Patients Treated by All US-Based AACS Members Practices.....III-6 1 $100     Factors to be Considered Prior to Cosmetic Botox Treatment.....III-7 Botox for Spasticity – Improved Quality of Life.....III-7 Coding and Reimbursement.....III-7 1 $100     US Cosmetic Market – Statistical Data.....III-8 Table 17: Cosmetic Market in the US (2004 & 2005): Leading Surgical Procedures (includes corresponding Graph/Chart).....III-8 1 $100     Table 18: Cosmetic Market in the US (2004 & 2005): Leading Non-Surgical Procedures (includes corresponding Graph/Chart).....III-9 Table 19: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Gender.....III-9 Table 20: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Age Group (includes corresponding Graph/Chart).....III-9 1 $100     Table 21: Number of Cosmetic Procedures in the US (2005): Percentage Breakdown by Facility (includes corresponding Graph/Chart).....III-10 Table 22: Cosmetic Market in the US (2004): Percentage Breakdown by Procedure Type.....III-10 Technological Development.....III-10 Strategic Corporate Developments.....III-10 3 $300     Key Players.....III-13 Allergan, Inc.....III-13 1 $100     Metabiologics Inc.....III-14 Mentor Corporation.....III-14 Solstice Neurosciences, Inc......III-14 1 $100     B. Market Analytics.....III-15 Table 23: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-15 Table 24: US 10-Year Perspective for Botulinum Toxin – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications for the Years 2000, 2006 & 2010.....III-15 1 $100   2. Rest of World.....III-16 6  $600       A. Market Analysis.....III-16 Current and Future Analysis.....III-16 Europe.....III-16 Botox Demand Increases with Zeal For Beauty.....III-16 Botox Approvals and Indications in Select European Countries.....III-16 1 $100     Botox to Support Radiation Treatments.....III-17 Asia.....III-17 India – An Emerging Market for Botox.....III-17 Korea – Fast Catching Up the Trend.....III-17 Australia – A Well Supported Market.....III-17 1 $100     Botox Approvals and Indications in Select Asian Countries.....III-18 Botox Approvals and Indications in Select Latin American Regions.....III-18 1 $100     Botox Approvals and Indications in Other Select Global Regions.....III-19 Strategic Corporate Developments.....III-19 1 $100     Key Players.....III-20 Ipsen Group (France).....III-20 Merz Pharmaceuticals GmbH (Germany).....III-20 1 $100     B. Market Analytics.....III-21 Table 25: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart).....III-21 Table 26: Rest of World 10-Year Perspective for Botulinum Toxin – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications for the Years 2000, 2006 & 2010.....III-21 1 $100 IV. COMPETITION 39 $995     1. Allergan, Inc. (USA).....IV-1 1 $27     Table 27: Nine Months Sales Analysis: 2006 Vs. 2005 (Nine Months Ended, September) (In US$ million).....IV-2 Table 28: Nine Months Sales Analysis by Segment: 2006 Vs. 2005 (Nine Months Ended, September) (In US$ million).....IV-2 Table 29: Annual Sales Analysis: 2005 Vs. 2004 (In US$ million).....IV-2 Table 30: Annual Sales Analysis by Quarter: 2005 Vs. 2004 (In US$ million).....IV-2 Table 31: Annual Sales Analysis by Product: 2005 Vs. 2004 (In US$ million).....IV-2 1 $27     Table 32: Annual Sales Analysis by Geographic Region: 2005 Vs. 2004 (In US$ million).....IV-3 3 $81     Allergan India Ltd. (India) .....IV-6 1 $27     2. Biotecon Therapeutics (Germany).....IV-7 1 $27     3. DOR Biopharma, Inc. (USA).....IV-8 Table 33: Annual Sales Analysis: 2004-2006 (In US$ thousands).....IV-8 Table 34: Annual Sales Analysis by Segment: 2006 Vs. 2005 (In US$ thousands).....IV-8 3 $81     4. DPS Technology Development Ltd. (China).....IV-11 1 $27     5. DreamPharma Corporation (South Korea).....IV-12 1 $27     6. Emergent Biosolutions, Inc. (USA).....IV-13 1 $27     Table 35: Annual Sales Analysis: 2005 Vs. 2004 (In US$ million).....IV-14 1 $27     7. Glaxosmithkline KK (Japan).....IV-15 1 $27     8. Ipsen Group (France).....IV-16 Table 36: Annual Sales Analysis: 2005 Vs. 2004 (In € million).....IV-16 3 $81     Ipsen Ltd. (UK) .....IV-19 1 $27     9. Medicis Pharmaceutical Corporation (USA).....IV-20 1 $27     Table 37: Half Yearly Sales Analysis: 2006 Vs. 2005 (H1) (In US$ million).....IV-21 Table 38: Half Yearly Sales Analysis by Quarter: 2006 Vs. 2005 (H1) (In US$ million).....IV-21 Table 39: Annual Sales Analysis: 2005 Vs. 2004 (In US$ million).....IV-21 4 $108     10. Medy-Tox, Inc. (South Korea).....IV-25 1 $27     11. Mentor Corporation (USA).....IV-26 1 $27     Table 40: Half Yearly Sales Analysis: 2007 Vs. 2006 (H1) (In US$ million).....IV-27 Table 41: Half Yearly Sales Analysis by Quarter: 2007 Vs. 2006 (H1) (In US$ million).....IV-27 1 $27     Table 42: Half Yearly Sales Analysis by Product: 2007 Vs. 2006 (H) (In US$ million).....IV-28 Table 43: Annual Sales Analysis: 2004-2006 (In US$ million).....IV-28 Table 44: Annual Sales Analysis by Quarter: 2006 Vs. 2005 (In US$ million).....IV-28 Table 45: Annual Sales Analysis by Product: 2006 Vs. 2005 (In US$ million).....IV-28 Table 46: Annual Sales Analysis by Geographic Region: 2006 Vs. 2005 (In US$ million).....IV-28 1 $27     Table 47: Annual Sales Analysis by Product: 2005 Vs. 2004 (In US$ million).....IV-29 Table 48: Annual Sales Analysis by Geographic Region: 2005 Vs. 2004 (In US$ million).....IV-29 6 $162     12. Merz Pharmaceuticals GmbH (Germany).....IV-35 2 $54     13. Metabiologics, Inc. (USA).....IV-37 1 $27     14. Shandong Ilongen Bio Technology Co., Ltd. (China).....IV-38 1 $27     15. Solstice Neurosciences, Inc. (USA).....IV-39 1 $27